ニュース

武田薬品、新型コロナウイルスワクチン「ヌバキソビッド筋注1mL ...
【プレスリリース】発表日:2025年06月27日SARS-CoV-2オミクロン株LP.8.1系統を抗原株とした新型コロナワクチン「ヌバキソビッド(R)筋注1mL」の承認事項一部変更承認申請について当社は、本日、SARS-CoV-2オミクロン株LP.8 ...
Kii Minpo13 日
NovavaxのCOVID-19ワクチンがPREVENT-19第3相試験で90％の全体的有効性と ...
Novavax, Inc.（Nasdaq：NVAX）は14日、同社のタンパク質ベースの組換えCOVID-19ワクチンNVX-CoV2373が、中等度および重度の疾患を100％予防、全体で90.4％の有効性を示し、第3相主試験PREVENT-19の主要評価項目を達成したと発表した。
BioSpace2 日
Novavax Approval Process a Potential ‘Harbinger’ of Threat to FDA Integrity: Former ...
Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...
Novavax's COVID-flu combo vaccine shows strong immune response in trial
Novavax's COVID-19-influenza vaccines show strong immune response in older adults, paving the way for regulatory approval.
Asianet Newsable on MSN3 日
Moderna, Pfizer, Novavax Draw Bearish Buzz Ahead Of CDC Panel With Vaccine Skeptics
RFK Jr.'s newly appointed CDC panel, half of whom oppose vaccines, prepares to review key data on COVID, RSV, and flu shots.
Stocktwits on MSN18 日
Novavax’s Covid-Flu Combo, Standalone Flu Vaccines Demonstrate Robust Immune Response In ...
Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates demonstrated a robust immune response in an initial cohort of a late-stage ...